Kissei Pharmaceutical Co., Ltd.
KSPHFOTCHealthcare● Active
$30.28
+$4.51(+17.50%)
Market Cap$1.3B
P/E Ratio—
52W High$31.9
52W Low$25.1
Kissei Pharmaceutical Co., Ltd. (KSPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KSPHF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$0.42
Est. $0.52 · -18.5%
Revenue
$0.16B
Est. $0.15B · +4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
KSPHF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.35 | — | — | — | $0.14B | — |
| ▼ Q2 FY2026 | May 11, 2026 | $0.52 | $0.42 | -18.5% | $0.16B | $0.15B | +4.3% |
| ▲ Q1 FY2026 | Jan 30, 2026 | -$0.25 | $0.50 | +302.5% | $0.17B | $0.16B | +6.9% |
| ▲ Q3 FY2025 | Aug 1, 2025 | $0.47 | $0.74 | +58.6% | $0.15B | $0.15B | +2.1% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.42 | $0.49 | +16.9% | $0.15B | $0.13B | +12.5% |
| ▼ Q1 FY2025 | Feb 3, 2025 | $0.54 | $0.53 | -2.8% | $0.15B | $0.14B | +6.5% |
| ▼ Q4 FY2024 | Nov 5, 2024 | $0.54 | $0.17 | -67.6% | $0.14B | — | — |
| ▲ Q3 FY2024 | Jul 30, 2024 | $0.38 | $0.58 | +51.2% | $0.13B | $0.12B | +7.1% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.35
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
$0.42
EPS Est.
$0.52
EPS Surpr.
-18.5%
Revenue
$0.16B
Q1 FY2026
Jan 30, 2026Beat
EPS Actual
$0.50
EPS Est.
-$0.25
EPS Surpr.
+302.5%
Revenue
$0.17B
Q3 FY2025
Aug 1, 2025Beat
EPS Actual
$0.74
EPS Est.
$0.47
EPS Surpr.
+58.6%
Revenue
$0.15B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.49
EPS Est.
$0.42
EPS Surpr.
+16.9%
Revenue
$0.15B
Q1 FY2025
Feb 3, 2025Miss
EPS Actual
$0.53
EPS Est.
$0.54
EPS Surpr.
-2.8%
Revenue
$0.15B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
$0.17
EPS Est.
$0.54
EPS Surpr.
-67.6%
Revenue
$0.14B
Q3 FY2024
Jul 30, 2024Beat
EPS Actual
$0.58
EPS Est.
$0.38
EPS Surpr.
+51.2%
Revenue
$0.13B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $43.03 | $43.03 | $43.03 | 1 |
| Q1 FY2027 | $79.09 | $79.09 | $79.09 | 1 |
| Q4 FY2026 | $62.15 | $62.15 | $62.15 | 1 |
| Q3 FY2026 | $47.66 | $47.66 | $47.66 | 1 |
| Q2 FY2026 | $55.91 | $55.91 | $55.91 | 1 |
| Q1 FY2026 | $82.45 | $82.45 | $82.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $24.5B | $24.5B | $24.5B | 1 |
| Q1 FY2027 | $24.0B | $24.0B | $24.0B | 1 |
| Q4 FY2026 | $19.8B | $19.8B | $19.8B | 1 |
| Q3 FY2026 | $21.9B | $21.9B | $21.9B | 1 |
| Q2 FY2026 | $22.5B | $22.5B | $22.5B | 1 |
| Q1 FY2026 | $23.0B | $23.9B | $24.8B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -18.5% | $25.77 | $25.77 | +0.00% |
| ▲ Q1 FY2026 | Jan 30, 2026 | +302.5% | $26.97 | $26.97 | +0.00% |
| ▲ Q3 FY2025 | Aug 1, 2025 | +58.6% | $27.13 | $27.13 | +0.00% |
| ▲ Q2 FY2025 | May 7, 2025 | +16.9% | $23.23 | $23.23 | +0.00% |
| ▼ Q1 FY2025 | Feb 3, 2025 | -2.8% | $23.26 | $23.26 | +0.00% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -67.6% | $25.00 | $25.00 | +0.00% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +51.2% | $19.32 | $19.32 | +0.00% |
| ▼ Q2 FY2024 | May 7, 2024 | -43.8% | $22.88 | $22.88 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 11, 2026
EPS Beat/Miss
-18.5%
Price Before
$25.77
Price After
$25.77
Q1 FY2026+0.00%
Report Date
Jan 30, 2026
EPS Beat/Miss
+302.5%
Price Before
$26.97
Price After
$26.97
Q3 FY2025+0.00%
Report Date
Aug 1, 2025
EPS Beat/Miss
+58.6%
Price Before
$27.13
Price After
$27.13
Q2 FY2025+0.00%
Report Date
May 7, 2025
EPS Beat/Miss
+16.9%
Price Before
$23.23
Price After
$23.23
Q1 FY2025+0.00%
Report Date
Feb 3, 2025
EPS Beat/Miss
-2.8%
Price Before
$23.26
Price After
$23.26
Q4 FY2024+0.00%
Report Date
Nov 5, 2024
EPS Beat/Miss
-67.6%
Price Before
$25.00
Price After
$25.00
Q3 FY2024+0.00%
Report Date
Jul 30, 2024
EPS Beat/Miss
+51.2%
Price Before
$19.32
Price After
$19.32
Q2 FY2024+0.00%
Report Date
May 7, 2024
EPS Beat/Miss
-43.8%
Price Before
$22.88
Price After
$22.88
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KSPHF ends December
Kissei Pharmaceutical Co., Ltd. (KSPHF) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $0.42 — missing the analyst consensus of $0.52 by -18.5%. The next KSPHF earnings date is expected around September 1, 2026.
Each quarter, investors track KSPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KSPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KSPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KSPHF earnings · 5 questionsKissei Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. KSPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KSPHF historically reports after market close (AMC).
KSPHF earnings datewhen is KSPHF earningsKSPHF next earnings datewhen does KSPHF report earningsKSPHF earnings calendar
▸ Source: FMP · Kissei Pharmaceutical Co., Ltd. SEC filings · US GAAP · Kissei Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026